Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

Richard E PratleyRoy EldorAnnaswamy RajiGregory GolmSusan B HuyckYanping QiuSheila SungaJeremy JohnsonSteven G TerraJames P MancusoSamuel S EngelBrett Lauring

Published in: Diabetes, obesity & metabolism (2018)

In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents.

Keyphrases

type diabetes
gestational age
glycemic control
cardiovascular disease
insulin resistance
metabolic syndrome